| SARS-CoV-2 reinfection #MMPMID34294235Romera I; Nunez K; Calizaya M; Baeza I; Molina R; Morillas JMed Intensiva (Engl Ed) 2021[Aug]; 45 (6): 375-376 PMID34294235show ga
ä|Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH]|Aged[MESH]|Alanine/analogs & derivatives/therapeutic use[MESH]|Antibodies, Monoclonal, Humanized/therapeutic use[MESH]|Antibodies, Viral/blood[MESH]|Antigens, Viral/blood[MESH]|Antiviral Agents/therapeutic use[MESH]|COVID-19 Drug Treatment[MESH]|COVID-19 Nucleic Acid Testing[MESH]|COVID-19 Serological Testing[MESH]|COVID-19/blood/diagnosis/*virology[MESH]|Combined Modality Therapy[MESH]|DNA, Viral/analysis[MESH]|Diabetes Mellitus, Type 2/complications[MESH]|Drug Therapy, Combination[MESH]|Dyslipidemias/complications[MESH]|Enzyme-Linked Immunosorbent Assay[MESH]|Humans[MESH]|Hyperuricemia/complications[MESH]|Immunoglobulin G/blood[MESH]|Immunoglobulin M/blood[MESH]|Luminescent Measurements[MESH]|Male[MESH]|Methylprednisolone/therapeutic use[MESH]|Nasopharynx/virology[MESH]|Polymerase Chain Reaction[MESH]|Reinfection/blood/diagnosis/*virology[MESH]
DeepDyve Pubget Overpricing |
|